NEW YORK–(BUSINESS WIRE)–Kroll Bond Rating Agency (KBRA) announces the preliminary ratings to two note classes of Drug Royalty III LP 1, Series 2018-1, a drug royalty securitization. This transaction is backed by royalty revenues from 15 royalty streams on 14 pharmaceutical products. The series 2018-1 notes will be the Issuer’s third series within the master trust and will be serviced by DRI Capital Inc. (“DRI”, or the “Company”). The other remaining series under the master trust are the 2016
